Summary report OECD/EUPHA - Long COVID Policy Dialogue
This publication is part of the “Supporting long COVID patients: insights and action initiative (2024-2026)” of the European Commission.
Adult Respiratory Vaccination Delivers Up to $12 in Societal Value for Every $1 Spent, Analysis Finds
Benefit-cost modeling estimated $22B annual spend produces $101B-$241B net benefits, preventing ~18,500 deaths and 300,000 hospitalizations in a single year.
#EURespiDay 2026 looks ahead to a Council Recommendation on respiratory virus immunisation for cardiovascular prevention
Organised by the Steering Group on Prevention of Respiratory Infections
Vaccination policies for healthcare personnel in Europe, 2026
European countries have more comprehensive vaccination policies for HCP compared with 2018, however there are still significant differences between countries.
Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season - COVID-19, RSV, Influenza
JAMA Special Communications - Three systematic reviews identify & summarise recent reporting on the effectiveness and safety of vaccines and influenza/RSV/Covid-19 epidemiology in the US.
(Recording available) IDC Partner Session at WOHC2026 - Exploring bidirectional links between respiratory viruses & non-communicable diseases
Now available to watch On Demand - IDC session at 9th World One Health Congress in Lisbon, 6 September 2026.
Sustained Reduction in Cardiopulmonary Fitness in Long COVID: A Report from the RECOVER-adult Cohort Study
Long COVID is associated with worse cardiovascular fitness. Additional studies are needed to determine if Long COVID is a novel risk factor for incident CVD.
Still Treating Yesterday's Risk? Reconsidering Antiviral Use for Mild-to-Moderate COVID-19 Cases in a Broadly Immune Population
Comparing the Australian and New Zealand experiences in the evolving COVID-19 landscape highlights differences in policy and prescribing practice.